Rare Copy Number Variants

A Point of Rarity in Genetic Risk for Bipolar Disorder and Schizophrenia

Detelina Grozeva, MSc; George Kirov, PhD, MRCPsych; Dobril Ivanov, MSc; Ian R. Jones, PhD, MRCPsych; Lisa Jones, PhD; Elaine K. Green, PhD; David M. St Clair, MD, PhD; Allan H. Young, PhD, FRCPsych; Nicol Ferrier, PhD, FRCPsych; Anne E. Farmer, PhD, FRCPsych; Peter McGuffin, PhD, FRCPsych; Peter A. Holmans, PhD*; Michael J. Owen, PhD, FRCPsych*; Michael C. O'Donovan, PhD, FRCPsych*; Nick Craddock, PhD, FRCPsych*; for the Wellcome Trust Case Control Consortium

Context: Recent studies suggest that copy number variation in the human genome is extensive and may play an important role in susceptibility to disease, including neuropsychiatric disorders such as schizophrenia and autism. The possible involvement of copy number variants (CNVs) in bipolar disorder has received little attention to date.

Objectives: To determine whether large (>100,000 base pairs) and rare (found in <1% of the population) CNVs are associated with susceptibility to bipolar disorder and to compare with findings in schizophrenia.

Design: A genome-wide survey of large, rare CNVs in a case-control sample using a high-density microarray.

Setting: The Wellcome Trust Case Control Consortium.

Participants: There were 1697 cases of bipolar disorder and 2806 nonpsychiatric controls. All participants were white UK residents.

Main Outcome Measures: Overall load of CNVs and presence of rare CNVs.

Results: The burden of CNVs in bipolar disorder was not increased compared with controls and was significantly less than in schizophrenia cases. The CNVs previously implicated in the etiology of schizophrenia were not more common in cases with bipolar disorder.

Conclusions: Schizophrenia and bipolar disorder differ with respect to CNV burden in general and association with specific CNVs in particular. Our data are consistent with the possibility that possession of large, rare deletions may modify the phenotype in those at risk of psychosis: those possessing such events are more likely to be diagnosed as having schizophrenia, and those without them are more likely to be diagnosed as having bipolar disorder.

Arch Gen Psychiatry. 2010;67(4):318-327
risk of a number of neuropsychiatric phenotypes, including autism, mental retardation, and schizophrenia.\textsuperscript{10,16}

The overall load of copy number variants (CNVs) has been shown to be greater in individuals with schizophrenia than controls.\textsuperscript{11,13,17} There is also convincing evidence for association between schizophrenia and a number of specific rare CNVs (<1% population frequency), particularly those at 22q11 (the velocardiofacial syndrome deletion), 1q21.1, and 15q13.3,\textsuperscript{12,13} and also to the class of rare CNVs larger than 1 megabase (Mb).\textsuperscript{14} Furthermore, some specific CNVs associated with risk of schizophrenia confer risk to multiple neuropsychiatric phenotypes, including autism, attention-deficit/hyperactivity disorder, and epilepsy (eg, 1q21.1, 15q13.3, 22q11.2, and 16p13.1).\textsuperscript{18,19} The estimated effect sizes for these CNVs are substantially greater than those conferred by the SNPs discussed earlier. However, the typical effect sizes and population frequencies of pathogenically relevant CNVs are not yet fully characterized, nor is the full extent to which CNVs contribute to the pathogenically relevant CNVs are not yet fully characterized, nor is the full extent to which CNVs contribute to the total population variance in risk of schizophrenia. The only systematic study to date for bipolar disorder did not find any increase in overall CNV load, although there was a nominally significant increase in “singleton” CNVs in cases compared with controls.\textsuperscript{20} There have been reports of specific CNVs in individuals with bipolar disorder, but none has addressed the question of whether CNVs show significant overrepresentation in cases compared with controls.\textsuperscript{21,22}

The aim of the present study was to investigate CNVs in a large sample of patients with bipolar disorder (n=1697) by means of data from a gene mapping system (GeneChip Human Mapping 500K Array Set; Affymetrix Inc, Santa Clara, California), genotyped in the Wellcome Trust Case Control Consortium (WTCCC) study.\textsuperscript{4} We compared the findings in our bipolar cases with those in a large sample of nonpsychiatric controls (n=2806) and also with a sample of cases meeting criteria for schizophrenia (n=440), all of whom were genotyped as part of the WTCCC pipeline with the use of identical methods.\textsuperscript{14}

**METHODS**

**SAMPLES**

The bipolar disorder cases and the controls are those reported by the WTCCC. A detailed description of the sample and methods has been published previously.\textsuperscript{4}

The bipolar disorder cases (n=1868) were older than 16 years, living in the United Kingdom, and of European white ancestry. Clinical assessment included semistructured interview and review of case notes. All patients received information and signed a consent form for participation in genetic studies. Of those, 1697 individuals passed the quality control (QC) filtering for the CNV analysis undertaken in the current study (described in the next section). The diagnoses according to Research Diagnostic Criteria were bipolar I disorder (n=1209), schizoaffective disorder bipolar type (n=243), bipolar II disorder (n=156), and manic disorder (n=89).

The controls were all white UK residents and were collected from 2 sources: the 1958 birth cohort and the UK Blood Service. It has previously been shown that these 2 control samples can be combined for use as controls in genetic association studies using UK disease samples, including the bipolar disorder sample.\textsuperscript{4} Of the 2938 controls, 2806 passed the QC filtering and were used for the CNV analysis (1411 individuals from the 1958 cohort and 1395 from the UK Blood Service sample).

**GENOTYPING AND CNV ANALYSIS**

The DNA from case and control samples were genotyped with the mapping array set at the laboratory of the manufacturer, as previously described.\textsuperscript{4} The array set consists of 2 arrays: NspI and StyI. On average, 250 000 SNPs were genotyped per array. It is possible to infer data for the copy number variation by using the intensity data of the SNP genotyping (CEL files). For exploring the copy number variation by using the intensity data from the SNP chip, Affymetrix Genotyping console v2.1 software was used (http://www.affymetrix.com). Because the SNP call rate is known to reflect sample quality, an initial basic QC filter was applied to the data (using the default parameters of the software) to exclude samples having an average SNP call rate less than 93%.

For reference sets we used samples from the same processing batches because using one reference set for all samples produced poor-quality data owing to systematic confounding effects. Because we sought to reduce to a minimum the false-positive rate of calling CNVs, we applied the same stringent QC filtering to the data that we used in our previous study of schizophrenia.\textsuperscript{14} A deletion or duplication was called only if it was 100 kilobase (kb) or greater in length and comprised 10 or more consecutive SNPs separately on each of the 2 arrays. The interquartile range (IQR) of the log, ratio was used to evaluate the quality of the arrays for the copy number analyses. Samples with an IQR greater than 0.40 (default parameter in the Affymetrix genotyping console v2.1 software) were excluded from the analysis. Samples with an IQR greater than 0.40 produced more than 20 deletions and/or duplications (and >100 CNVs when the IQR was \(\geq 0.50\)), suggesting that observations corresponding to 20 or more CNV segments per person were likely to be false-positives. Therefore, samples with more than 20 segments were also excluded even if the observed IQR was 0.40 or less.

We accepted only deletions or duplications found independently on both arrays, with the overlap of the segments identified by the StyI and the NspI arrays of 100 kb or greater. Segments were matched by means of a stand-alone program developed in-house (available at http://s001-psycm.uwcm.ac.uk/). We also excluded any CNVs that had very low SNP density (<3 SNPs per 100 kb) because these tend to intersect low copy repeats or “difficult-to-sequence” regions of the genome and have an increased probability of being false-positives. After these stringent QC filter criteria were applied, 1697 cases and 2806 controls were retained for analysis.

Because there are difficulties in using this method to genotype common CNVs and consistent with recent studies using this approach,\textsuperscript{14} common CNVs (found in \(\geq 1\%\) of the samples) were excluded. Any CNVs that overlapped by more than 50% of their length with common CNVs were also excluded. Using PLINK\textsuperscript{14} version 1.05, all rare deletions and duplications that remained after these criteria were listed in a custom track for visualization in UCSC Genome Browser (University of California, Santa Cruz; http://genome.ucsc.edu/), available at http://s004-psycm.uwcm.ac.uk/\~detelina/.

We had previously performed a similar analysis on cases affected with schizophrenia recruited from the same population compared against the same set of WTCCC controls.\textsuperscript{15} As part of that study, we validated 22 CNVs (most of them >1 Mb) with a second platform (Human Genome CGH Microarray Kit 44K; Agilent Technologies, Santa Clara, California). All validated correctly, reflecting our stringent filtering criteria and the fact that each CNV had already been called independently by 2 arrays (StyI and NspI). We therefore did not attempt to validate any CNVs in the current study.
STATISTICAL ANALYSIS

The CNV association analyses were performed with PLINK\textsuperscript{24} version 1.05, obtained from http://pngu.mgh.harvard.edu/~purcell/plink/.

The \( P \) values throughout this article are 2-tailed, based on comparing the rate of CNVs in 2 independent samples (usually cases vs controls), and were derived with the use of 10,000 permutations. The genomic coordinates used in the study are based on the March 2006 human genome sequence assembly (UCSC Hg18, National Center for Biotechnology Information build 36).

RESULTS

GLOBAL BURDEN OF CNVs

The total number of rare CNVs, and the corresponding \( P \) value from the comparison between cases and controls, are presented in Table 1. The rate of CNVs was not increased in bipolar disorder cases compared with controls, and there was even a nominally significant association in the opposite direction for deletions (\( P = .01 \)) (see the supplementary Results section for more details and a breakdown of these results according to CNV size in eTable 1; available at: http://www.archgenpsychiatry.com).

Although we did not observe an overall increase in CNV burden in bipolar cases compared with controls, some individual CNVs were more common in cases than controls (although none showed a significant association after correction for multiple testing). These CNVs are shown in eTable 2. We did not observe any CNV events in cases in the few regions in which there have been reports of CNV events in individuals with bipolar disorder (for details see the supplementary Results section).

ANALYSIS OF SINGLETON CNVs

To test the recent report of an increased rate of rare singleton CNV events in bipolar disorder,\textsuperscript{20} we estimated the global burden of single-occurrence deletions and single-occurrence duplications. We found no difference between the proportion of cases and controls with singleton CNVs as a whole or when deletions and duplications were considered separately (Table 2). The previous report\textsuperscript{20} observed that singleton deletions were particularly more common in cases with mania with an onset of illness before age 18 years. In the 65 patients in our sample with such an early age at onset, there was no difference in the rate of singleton CNVs compared with the rest of the sample (data not shown).

Further details about the analysis of the singleton events, and genes affected by CNVs only in cases, can be found in the supplementary Results section (eTable 3).

ANALYSIS RESTRICTED TO CNVs LARGER THAN 1 Mb

In our study of schizophrenia using the same methods and samples from the same UK population,\textsuperscript{14} we observed a significant increase in CNV load only for CNVs larger than 1 Mb. We therefore undertook an analysis of this category in bipolar disorder (Table 3). There were no significant differences between cases and controls; indeed, the trend was toward fewer CNV events in bipolar disorder cases.

When we compared our bipolar disorder cases against our set of schizophrenia cases that had been examined for this class of CNVs by the same methods\textsuperscript{14} (\( n = 440 \)), we observed a significant excess in the schizophrenia cases for deletions and total CNVs (both \( P < .001 \)). There was also a trend toward an excess of large duplications (\( P = .053 \)) in schizophrenia compared with bipolar disorder. The rate of large CNVs in schizophrenia cases was approximately 5-fold higher for deletions and approximately 2-fold higher for duplications compared with the bipolar cases (eTable 1). It should be noted that the \( P \) values reported herein for the comparison between schizophrenia cases and controls vary slightly from those published in our schizophrenia-

### Table 1. Global Copy Number Variant (CNV) Burden in Cases and Controls

<table>
<thead>
<tr>
<th></th>
<th>Cases (n=1697)</th>
<th>Controls (n=2806)</th>
<th>( P ) Valuea</th>
<th>No. of CNVs</th>
<th>No./Individual</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deletion</td>
<td>324</td>
<td>0.19</td>
<td></td>
<td>632</td>
<td>0.23</td>
</tr>
<tr>
<td>Duplication</td>
<td>538</td>
<td>0.32</td>
<td></td>
<td>901</td>
<td>0.32</td>
</tr>
<tr>
<td>Total</td>
<td>862</td>
<td>0.51</td>
<td></td>
<td>1533</td>
<td>0.55</td>
</tr>
</tbody>
</table>

a Empirical 2-sided \( P \) value based on 10,000 permutations.

b Note that this significant result is for fewer CNVs in cases than controls.

### Table 2. Global Burden of Singleton Copy Number Variants (CNVs)

<table>
<thead>
<tr>
<th>Single CNV Type</th>
<th>Cases (n=1697)</th>
<th>Controls (n=2806)</th>
<th>CNV per Case</th>
<th>CNV per Control</th>
<th>Case to Control Ratio</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deletion</td>
<td>104</td>
<td>179</td>
<td>0.06</td>
<td>0.06</td>
<td>0.96</td>
<td>.77</td>
</tr>
<tr>
<td>Duplication</td>
<td>130</td>
<td>251</td>
<td>0.08</td>
<td>0.09</td>
<td>0.86</td>
<td>.17</td>
</tr>
<tr>
<td>Deletion + duplication</td>
<td>203</td>
<td>355</td>
<td>0.12</td>
<td>0.13</td>
<td>0.95</td>
<td>.55</td>
</tr>
</tbody>
</table>

©2010 American Medical Association. All rights reserved.
nia report because of exclusion of schizoaffective cases from the current analysis. Further details are provided in the supplementary Results section.

ANALYSIS RESTRICTED TO CNVs THAT DISRUPT GENES

Following a previous study of schizophrenia, we examined in the bipolar cases the burden of CNVs that delete, duplicate, or disrupt genes (method described in the supplementary Results section). This analysis was performed for all CNVs and then for CNVs that occurred only once in the data. Again, no significant differences were found (data not shown). A list of all genes disrupted in CNVs in cases that were not disrupted in any controls is provided in eTable 4.

ANALYSIS OF CNVs PREVIOUSLY REPORTED TO BE ASSOCIATED WITH RISK OF SCHIZOPHRENIA

Table 4 shows the main chromosomal regions reported to be associated with schizophrenia and the respective number of the observed CNVs in the bipolar disorder cases and in the controls. We have included only loci reported in multiple studies or with strong statistical support from at least 1 large study.

The total burden of these specific rare CNVs that have been associated with risk of schizophrenia was not increased in bipolar disorder cases compared with controls (frequency per individual: cases, 0.010; controls, 0.016). Only 2 regions showed a trend for overrepresentation in cases. Duplications at 16p11.2 were found in 3 cases and 1 control, a 5-fold increase in frequency (0.2% vs 0.04%; Fisher exact test, \( P = .15 \)). One of these had arisen de novo and was not present in the proband’s father, who also had bipolar disorder (see the supplementary Results section). Two cases and no controls had duplications of 15q13.3, deletion of which has been confirmed to confer susceptibility to schizophrenia. More information on the loci in Table 4 is given in the supplementary Results section.

We have undertaken a comparison of the occurrence of rare CNVs in a large white UK set of bipolar cases and controls using genome-wide SNP data generated within the WTCCC study. In contrast to several recent reports of an increased burden of rare CNVs, particularly large deletions, in schizophrenia cases compared with controls, we observed no such increase in bipolar disorder cases, and there was even a trend toward a reduced rate for deletions. Furthermore, direct comparison of our bipolar disorder cases with our set of schizophrenia cases recruited from the same UK clinical population, assessed by similar clinical methods and analyzed by means of the same genotyping platform, QC filtering, and statistical methods, showed that deletions greater than 1 Mb were about 5 times more common in the schizophrenia cases (\( P < .001 \)). Thus, our data demonstrate a significant difference between bipolar disorder and schizophrenia with respect to global burden of rare and large CNVs.

In addition, we did not find evidence of even a trend toward an increase in bipolar disorder in the frequency of specific CNVs that have been reported to show a robust...
association with schizophrenia. It is important to recognize that power to detect a significant association at any specific rare CNV is low, although our power to detect the joint association of the 4 robustly schizophrenia-associated deletions (1q21.1, 15q11.2, 15q13.3, and 22q11.2) at $P < .05$ exceeds 96%. It is of particular interest that we observed no instances of a 22q11 deletion in our bipolar sample. In contrast, in our much smaller schizophrenia sample we observed 2 such deletions. Thus, our data do not support the hypothesis that 22q11 deletion syndrome (associated with velocardiofacial syndrome) is associated with bipolar disorder, as others have suggested.37 The only locus implicated in schizophrenia that showed a trend for overrepresentation in bipolar cases was duplication at 16p11.2, with a 5-fold increased rate over controls, but this did not reach statistical significance.

Genetic epidemiology suggests the existence of some genetic factors that confer risk to both schizophrenia and bipolar disorder and others that confer relatively specific risk to one or other of the dichotomous categories.35,36 A recent study of approximately 10,000 individuals has provided strong evidence of association between bipolar disorder and SNPs within 2 genes involved in ion channel function: ANK3 and CACNA1C.3 The SNP in CACNA1C that was most strongly associated with bipolar disorder shows a similar magnitude of association in UK schizophrenia and unipolar depression samples.33 Thus, variation at this locus influences susceptibility across the mood-psychosis spectrum. A study of approximately 20,000 individuals has provided strong evidence of association between schizophrenia and an SNP within 2NF804A (encoding a protein of unknown function, but that, on the basis of sequence similarity, may act as a transcription factor).25 The same SNP in 2NF804A also showed evidence of association with bipolar disorder,25 again demonstrating that variation at this locus also has an effect on illness susceptibility across the traditional diagnostic boundaries. Thus, for 2 of the recent strongly supported SNP associations that have been reported with the use of large samples and GWAS methods, there is evidence of an overlap in susceptibility across the traditional Kraepelinian dichotomy. Further recent support for the existence of shared genetic risk comes from the observation of overlapping sets of genes showing gene-wide significance in a gene-based analysis of genome-wide SNP data for bipolar disorder and schizophrenia.30 In contrast, the CNV findings to date suggest that copy number variation may have a relatively specific influence on susceptibility to illness that meets diagnostic criteria for schizophrenia.

This possibility has substantial face validity in that CNVs are known to be associated with some persistent neuropsychiatric phenotypes that are known to occur in, or be risk factors for, illnesses that meet diagnostic criteria for schizophrenia, including mental retardation, epilepsy, and autism.18,19 Thus, CNVs may predispose to persistent brain dysfunctions that affect intellectual functioning and personality development that may modify expression of the phenotype in those who have a propensity to develop psychoses.39,40

In our analyses, we found that the CNV burden was lower in our bipolar disorder cases than controls, and this difference was statistically significant when deletions were considered separately (Table 1; $P = .01$). Because this finding is not highly significant in the context of multiple testing, it may well be a chance finding, and therefore we consider that our data should be interpreted conservatively as showing no increase in burden of CNVs in bipolar cases compared with controls.

To our knowledge, there has been only 1 previous systematic genome-wide CNV analysis in bipolar disorder20, like the present study, it showed no increase in the total burden of CNVs in cases compared with controls. However, our data do not replicate the finding of a significant increase in singleton CNV events in bipolar cases compared with controls. Our study is larger than that of Zhang et al,20 and power exceeded 95% to detect the reported effect size at $P < .05$. Power is obviously lower if there is a true, but smaller, increase in singleton CNV burden or if our stringent QC method resulted in our detecting a smaller proportion of the relevant loci. With respect to very weak effects, no single study can provide definitive results, and therefore in this context a type II error in the present bipolar vs control analysis study cannot be fully discounted. However, the findings of Zhang and colleagues are much weaker than those reported in much smaller studies of schizophrenia and autism, and it is possible the results of that study represent a type I error because they would not withstand correction for testing multiple plausible hypotheses concerning CNV size, type, and frequency. Although additional studies will be required to finally resolve this discrepancy, our study does provide strong evidence that any contribution to bipolar disorder from CNVs in the size range we tested for is significantly smaller than it is to schizophrenia.

Although we have no evidence to support any specific locus, even single observations of occurrence of a CNV in a disorder can ultimately make an important contribution to understanding of disease pathogenesis, eg, the observation of a rare deletion in the NRXN1 gene in a proband with schizophrenia.34 To facilitate this, and downstream meta-analyses, we presented the full list of rare CNVs found in cases and controls in our supplementary material.

The strengths of our study include the large sample size, the rigorous QC filtering used, and our ability to make direct comparisons between bipolar disorder and schizophrenia cases that have been recruited from similar clinical populations and analyzed by means of the same genotyping pipeline and statistical methods. Some important limitations are inherent in all studies of CNVs. The first, as mentioned earlier, concerns power to detect very small increases in CNV burden. Second, CNV analyses using SNP data are not straightforward and require several analytic steps that are difficult to standardize precisely across studies by different investigators. This does not, however, affect comparisons across our own bipolar disorder and schizophrenia samples. The genotyping platform used in the WTCCC study (Affymetrix 500K chip) was one of the earliest GWAS genotyping platforms and, hence, has less resolution for CNVs than later platforms. This has much less influence on large CNVs (the focus of our study) but, because of this limitation, we have not tested the contribution of smaller CNVs (<100 kb) to disease susceptibility. In the future, it will
Members of Wellcome Trust Case Control Consortium

Management Committee
Paul R. Burton, Genetic Epidemiology Group, Department of Health Sciences, University of Oxford, Oxford, England; David G. Clayton, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, England; Nick Craddock, Department of Psychological Medicine, School of Medicine, Cardiff University, Cardiff, Wales; Panos Deloukas, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge; Audrey Duncanson, Wellcome Trust, London, England; Dominic P. Kwiatkowski, Wellcome Trust Centre for Human Genetics and Wellcome Trust Sanger Institute, Hinxton, Cambridge; Mark I. McCarthy, Wellcome Trust Centre for Human Genetics and Oxford Centre for Diabetes, Endocrinology, and Medicine, University of Oxford; Willem H. Ouwehand, Department of Haematology, University of Cambridge, and National Health Service Blood and Transplant, Cambridge Centre, Cambridge; Nilesh J. Samani, Department of Cardiovascular Sciences, University of Leicester; John A. Todd, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; and Peter Donnelly (chair), Department of Statistics, University of Oxford.

Data and Analysis Committee
Jeffrey C. Barrett, Wellcome Trust Centre for Human Genetics, University of Oxford; Paul R. Burton Genetic Epidemiology Group, Department of Health Sciences, University of Leicester; Dan Davison, Department of Statistics, University of Oxford; Peter Donnelly, Department of Statistics, University of Oxford; Anubhav Easton, Cancer Research UK Genetics Epidemiology Unit, Strangeways Research Laboratory, Cambridge; David M. Evans, Wellcome Trust Centre for Human Genetics, University of Oxford; Hin-Tak Leung, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; Jonathan L. Marchini, Department of Statistics, University of Oxford; Andrew P. Morris, Wellcome Trust Centre for Human Genetics, University of Oxford; Chris C. A. Spencer, Department of Statistics, University of Oxford; Martin D. Tobin, Genetic Epidemiology Group, Department of Health Sciences, University of Leicester; John A. Todd, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; and David G. Clayton (co-chair), Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge.

UK Blood Services and University of Cambridge Controls
Antony P. Attwood, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, and Department of Haematology, University of Cambridge; James P. Boorman, Department of Haematology, University of Cambridge, and National Health Service Blood and Transplant, Cambridge Centre; Barbara Cant, Department of Haematology, University of Cambridge; Ursula Esverson, National Health Service Blood and Transplant, Sheffield Centre, Sheffield, England; Judith M. Hussey, National Health Service Blood and Transplant, Brentwood Centre, Brentwood, England; Jennifer D. Jolley, Alexandra S. Knight, and Kerstin Koch, Department of Haematology, University of Cambridge; Elizabeth Meech, Welsh Blood Service, Pontyclun, Wales; Sarah Nutland, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; Willem H. Ouwehand, Department of Haematology, University of Cambridge, and National Health Service Blood and Transplant, Cambridge Centre; Christopher V. Prowse, Scottish National Blood Transfusion Service, Edinburgh, Scotland; Helen E. Stevens, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; Niall C. Taylor, Department of Haematology, University of Cambridge; John A. Todd, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; Neil M. Walker, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; Graham R. Walters, National Health Service Blood and Transplant, Southampton Centre, Southampton, England; Nicholas A. Watkins, Department of Haematology, University of Cambridge, and National Health Service Blood and Transplant, Cambridge Centre; and Thilo Winzer, Department of Haematology, University of Cambridge.

1958 Birth Cohort Controls
Richard W. Jones, Avon Longitudinal Study of Parents and Children, University of Bristol, Bristol, England; Wendy L. McArule and Susan M. Ring, Avon Longitudinal Study of Parents and Children, University of Bristol; Marcus Pembrey, Avon Longitudinal Study of Parents and Children, University of Bristol, and Institute of Child Health, University College London; and David P. Strachan, Division of Community Health Services, St George’s University of London.

Bipolar Disorder
Aberdeen, Scotland: Gerome Breen and David M. St Clair, University of Aberdeen, Institute of Medical Sciences. Birmingham, England: Sian Caesar, Katherine Gordon-Smith (also Department of Psychological Medicine, Henry Wellcome Building, School of Medicine, Cardiff University), and Lisa Jones, Department of Psychiatry, Division of Neuroscience, Birmingham University. Cardiff: Nick Craddock, Christine Fraser, Elaine K. Green, Detelina Grozeva, Mariann L. Hamshere, Peter A. Holmans, Ian R. Jones, George Kirov, Valentina Moskvina, Ivan Nikolov, Michael C. O’Donovan, and Michael J. Owen, Department of Psychological Medicine, Henry Wellcome Building, School of Medicine, Cardiff University. London: David A. Collier, Amanda Elkin, Anne E. Farmer, Peter McGuffin, and Richard Williamson, Social, Genetic, and Developmental Psychiatry Center, Institute of Psychiatry, King’s College London. Newcastle, England: I. Nicoll Ferrier and Allan H. Young, School of Neurology, Neurobiology, and Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne.

(continued)
Members of Wellcome Trust Case Control Consortium (continued)

Coronary Artery Disease

Leeds, England: Stephen G. Ball, Anthony J. Balmforth, Jennifer H. Barrett, D. Timothy Bishop, Alistair S. Hall, Mark M. Iles, Azhar Maqbool, and Nadira Yuldasheva, Leeds Institute of Genetics, Health, and Therapeutics and Leeds Institute of Molecular Medicine, Faculty of Medicine and Health, University of Leeds. Leicester: Peter S. Braun, Richard J. Dixon, Massimo Mangino, Nilesh J. Samani, and Suzanne Stevens, Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital; and Paul R. Burton, Martin D. Tobin, and John R. Thompson, Genetic Epidemiology Group, Department of Health Sciences, University of Leicester.

Crohn Disease

Cambridge: Francesca Bredin, Miles Parkes, and Mark Tremelling, Inflammatory Bowel Disease Research Group, Addenbrooke's Hospital, University of Cambridge. Edinburgh: Hazel Drummond, Charles W. Lees, Elaine R. Nimmo, and Jack Satsangi, Gastrointestinal Unit, School of Molecular and Clinical Medicine, University of Edinburgh, Western General Hospital. London: Sheila A. Fisher, Cathryn M. Lewis, Christopher G. Mathew, Clive M. Onnie, and Natalie J. Prescott, Department of Medical and Molecular Genetics, King's College London School of Medicine, Guy's Hospital, London; Alastair Forbes, Institute for Digestive Diseases, University College London Hospitals Trust; and Jeremy Sanderson, Department of Gastroenterology, Guy's and St Thomas' NHS (National Health Service) Foundation Trust, London. Newcastle: Jamie Barbour, John C. Mansfield, M. Khalid Mohiuddin, and Catherine E. Todhunter, Department of Gastroenterology and Hepatology, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne. Oxford: Tariq Ahmad, Fraser R. Cummings, and Derek P. Jewell, Gastroenterology Unit, Radcliffe Infirmary, University of Oxford.

Hypertension

Aberdeen: John Webster, Medicine and Therapeutics, Aberdeen Royal Infirmary, Foresterhill, Aberdeen. Cambridge: Morris J. Brown, Clinical Pharmacology Unit and Diabetes and Inflammation Laboratory, University of Cambridge, Addenbrooke's Hospital; and David G. Clayton, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge. Evry, France: G. Mark Lathrop, Centre National de Genotypage. Glasgow, Scotland: John Connell and Anna Dominiczak, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow. Leicester: Nilesh J. Samani, Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital. London: Carolina A. Braga Marcano, Beverley Burke, Mark Caulfield, Richard Dobson, Johannie Gungadoo, Kate L. Lee, Patricia B. Munroe, Stephen J. Newhouse, Abiodun Onipinla, Chris Wallace, and Mingzhe Xue, Clinical Pharmacology and Barts and The London Genome Centre, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine. Oxford: Martin Farrall, Cardiovascular Medicine, University of Oxford, Wellcome Trust Centre for Human Genetics.

Rheumatoid Arthritis

Anne Barton, Ian N. Bruce, Hannah Donovan, Steve Eyre, Paul D. Gilbert, Samantha L. Hider, Anne M. Hinks, Sally L. John, Catherine Potter, Alan J. Silman, Deborah P. M. Symmons, Wendy Thomson, and Jane Worthington, arc Epidemiology Research Unit, University of Manchester, Manchester, England.

Type 1 Diabetes

David G. Clayton, Sarah Nutland, Helen E. Stevens, John A. Todd, and Neil M. Walker, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; David B. Dunger and Barry Widmer, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, and Department of Paediatrics, University of Cambridge, Addenbrooke's Hospital, Cambridge.

Type 2 Diabetes

Exeter, England: Timothy M. Frayling, Rachel M. Freathy, Andrew T. Hattersley, Hana Lango, John R. B. Perry, and Michael N. Weedon, Genetics of Complex Traits, Institute of Biomedical and Clinical Science, and Diabetes Genetics, Institute of Biomedical and Clinical Science, Peninsula Medical School; and Beverley M. Shields, Diabetes Genetics, Institute of Biomedical and Clinical Science, Peninsula Medical School. London: Graham A. Hitman, Centre for Diabetes and Metabolic Medicine, Barts and The London, Royal London Hospital. Newcastle: Mark Walker, Diabetes Research Group, School of Clinical Medical Sciences, Newcastle University. Oxford: Kate S. Elliott, Cecilia M. Lindgren, Mark I. McCarthy, Nigel W. Rayner, and Eleftheria Zeggini, Wellcome Trust Centre for Human Genetics and Oxford Centre for Diabetes, Endocrinology, and Medicine, University of Oxford; Christopher J. Groves, Oxford Centre for Diabetes, Endocrinology, and Medicine, University of Oxford; and Nicholas J. Timpson, Wellcome Trust Centre for Human Genetics, University of Oxford, and the Medical Research Council Centre for Causal Analyses in Translational Epidemiology, Bristol University.

Tuberculosis


Ankylosing Spondylitis

Linda A. Bradbury and Jennifer J. Pointon, Diamantina Institute for Cancer, Immunology, and Metabolic Medicine, Princess Alexandra Hospital, University of Queensland, Woollongabba, Queensland, Australia; Claire Farrar and Paul Wordsworth, Botnar Research Centre, University of Oxford; and Matthew A. Brown, Diamantina Institute for Cancer, Immunology, and Metabolic Medicine, Princess Alexandra Hospital, University of Queensland, and Botnar Research Centre, University of Oxford.
Members of Wellcome Trust Case Control Consortium (continued)

Autoimmune Thyroid Disease
Jayne A. Franklyn, Stephen C. L. Gough, Joanne M. Heward, and Matthew J. Simmonds, Department of Medicine, Division of Medical Sciences, Institute of Biomedical Research, University of Birmingham.

Breast Cancer
Nazneen Rahman and Sheila Seal, Section of Cancer Genetics, Institute of Cancer Research, Sutton, England; and Michael R. Stratton, Section of Cancer Genetics, Institute of Cancer Research, Sutton, and Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus.

Multiple Sclerosis
Maria Ban, Alastair Compston, An Goris, and Stephen J. Sawcer, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge.

Gambian Controls
Gambia: David Conway, Muminatou Jallow, Melanie Newport, and Giorgio Sirugo, Medical Research Council Laboratories. Oxford: Kirk A. Rockett, Wellcome Trust Centre for Human Genetics, University of Oxford; and Dominic P. Kwiatkowski, Wellcome Trust Centre for Human Genetics, University of Oxford, and Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus.

DNA, Genotyping, Data Quality Control, and Informatics
Wellcome Trust Sanger Institute, Hinxton: Suzannah J. Bumpstead, Amy Chaney, Panos Deloukas, Kate Downes (also Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge), Mohammad J. R. Gholi, Rhiain Gwilliam, Sarah E. Hunt, Michael Inouye, Andrew Keniry, Emma King, Ralph McGinnis, Simon Potter, Rathi Ravindrarajah, Pamela Whittaker, Claire Widden, and David Withers. Cambridge: Hin-Tak Leung, Sarah Nutland, Helen E. Stevens, John A. Todd, and Neil M. Walker, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge.

Statistics
Cambridge: Doug Easton, Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge; and David G. Clayton, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge. Leicester: Paul R. Burton and Martin D. Tobin, Genetic Epidemiology Group, Department of Health Sciences, University of Leicester. Oxford: Jeffrey C. Barrett, Lon R. Cardon, David M. Evans, and Andrew P. Morris, Wellcome Trust Centre for Human Genetics, University of Oxford. Oxford: Niall J. Cardin, Dan Davison, Teresa Ferreira, Ingolf B. Hallgrimsdottir, Bryan N. Howie, Jonathan L. Marchini, Joanne Pereira-Gale, Chris C. A. Spencer, Zhan Su, Ying Ying Teo (also Wellcome Trust Centre for Human Genetics, University of Oxford), Damjan Vukcevic, and Peter Donnelly, Department of Statistics, University of Oxford.

Principal Investigators
David Bentley, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus (now with Illumina Cambridge, Chesterford Research Park, Little Chesterford, Nr Saffron Walden, Essex, England); Matthew A. Brown, Diamantina Institute for Cancer, Immunology, and Metabolic Medicine, Princess Alexandra Hospital, University of Queensland, and Botnar Research Centre, University of Oxford; Lon R. Cardon, Wellcome Trust Centre for Human Genetics, University of Oxford; Mark Caulfield, Clinical Pharmacology and Barts and The London Genome Centre, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine; David G. Clayton, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; Alistair Compston, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital; Nick Craddock, Department of Psychological Medicine, Henry Wellcome Building, School of Medicine, Cardiff University; Panos Deloukas, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus; Peter Donnelly, Department of Statistics, University of Oxford; Martin Farrall, Cardiovascular Medicine, University of Oxford, Wellcome Trust Centre for Human Genetics; Stephen C. L. Gough, Department of Medicine, Division of Medical Sciences, Institute of Biomedical Research, University of Birmingham; Alistair S. Hall, Leeds Institute of Genetics, Health, and Therapeutics and Leeds Institute of Molecular Medicine, Faculty of Medicine and Health, University of Leeds; Andrew T. Hattersley, Genetics of Complex Traits and Diabetes Genetics, Institute of Biomedical and Clinical Science, Peninsula Medical School; Adrian V. S. Hill, Wellcome Trust Centre for Human Genetics, University of Oxford; Dominic P. Kwiatkowski, Wellcome Trust Centre for Human Genetics, University of Oxford, and Oxford Trust Sanger Institute, Wellcome Trust Genome Campus; Christopher G. Mathew, Department of Medical and Molecular Genetics, King's College London School of Medicine, Guy's Hospital; Mark I. McCarthy, Wellcome Trust Centre for Human Genetics and Oxford Centre for Diabetes, Endocrinology, and Medicine, University of Oxford; Willem H. Ouwehand, Department of Haematology, University of Cambridge, and National Health Service Blood and Transplant, Cambridge Centre; Miles Parkes, Inflammatory Bowel Disease Research Group, Addenbrooke's Hospital, University of Cambridge; Marcus Pembrey, Avon Longitudinal Study of Parents and Children, University of Bristol, and Institute of Child Health, University College London; Nazneen Rahman, Section of Cancer Genetics, Institute of Cancer Research, Sutton; Nilesh J. Samani, Department of Cardiovascular Sciences, University of Leicester; Michael R. Stratton, Section of Cancer Genetics, Institute of Cancer Research, Sutton, and Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus; John A. Todd, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge; and Jane Worthington, arc Epidemiology Research Unit, University of Manchester.
be important to undertake further studies that use much higher-resolution platforms and that allow CNVs to be called at similar levels of accuracy as SNPs to provide further information about a wider spectrum of CNV sizes. The number of CNVs increases exponentially with smaller CNV size,31 so most CNVs remain to be identified and examined for association with disease.

Finally, CNV burden analysis alone cannot identify specific risk factors; nevertheless, the approach we present herein has proved pivotal in pointing to the involvement of CNVs in schizophrenia and other disorders.

In conclusion, we have used genome-wide association data to undertake a comparison of CNV burden in a large sample of bipolar disorder cases, nonpsychiatric controls, and schizophrenia cases. We found that CNV load was not elevated in bipolar disorder compared with controls and that deletions larger than 1 Mb were less common in probands with bipolar disorder than in those with schizophrenia. Our findings suggest that schizophrenia and bipolar disorder differ with respect to CNV burden in general and association with specific schizophrenia-associated CNVs in particular.

Submitted for Publication: March 27, 2009; final revision received June 26, 2009; accepted August 18, 2009. Author Affiliations: Medical Research Council Centre for Neuropsychiatric Genetics and Genomics (Ms Grozeva; Drs Kirov, I. R. Jones, Green, Holmans, Owen, O’Donovan, and Craddock; and Mr Ivanov), and Biostatistics and Bioinformatics Unit (Mr Ivnov and Dr Holmans), School of Medicine, Cardiff University, Cardiff, Wales; Department of Psychiatry, University of Birmingham, National Centre for Mental Health, Birmingham, England (Dr L. Jones); Institute of Medical Sciences, University of Aberdeen, Aberdeen, Scotland (Dr St Clair); School of Neurology, Neurobiology and Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, England (Drs Young and Ferrier); Institute of Mental Health, University of British Columbia, Vancouver, British Columbia, Canada (Dr Young); and Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, King’s College London, London, England (Drs Farmer and McGuffin).

Correspondence: Nick Craddock, PhD, FRCPsych, and George Kirov, PhD, MRCPsych, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff CF14 4XN, Wales (craddockn@cardiff.ac.uk, kirov@cardiff.ac.uk).

Financial Disclosure: None reported.

Funding/Support: Funding for recruitment and phenotype assessment was provided by the Wellcome Trust and the Medical Research Council. The genotype analyses were funded by the Wellcome Trust and undertaken within the context of the Wellcome Trust Case Control Consortium.


Additional Contributions: We are indebted to all individuals who have participated in or helped with our research, particularly those involved in the Bipolar Disorder Research Network (http://bdmr.org). The staff and members of MDF The Bipolar Organisation provided assistance, and Masashi Ikeda, MD, PhD, and Irina Zahrarieva, MSc, performed the validation experiments with Illumina arrays.


